Study guide
7.4 Pulmonary Embolism, Pulmonary Hypertension & Transport Respiratory Meds
IBSC CCP-C Certified Critical Care Paramedic Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Strategy
1.1 About the CCP-C Exam 1.2 CCP-C Study Strategy & Exam Tactics
2 Chapter 2: Transport and Safety (Part 1)
2.1 Crew Resource Management & Sterile Cockpit Rule 2.2 Transport Risk Assessment & Mission Decision-Making 2.3 Aircraft and Ground Transport Safety Protocols
3 Chapter 2: Transport and Safety (Part 2)
2.4 Environmental Transport Stressors & Gas Laws 2.5 Transport Equipment Management & Post-Mission Operations
4 Chapter 3: Airway, Anesthesia, and Analgesics (Part 1)
3.1 Advanced Airway Assessment & Difficult Airway Identification 3.2 Rapid Sequence Induction (RSI) - Pretreatment & Induction Agents 3.3 Neuromuscular Blockade - Depolarizing vs Non-Depolarizing Agents 3.4 Post-Intubation Sedation, Analgesia & Dissociative Maintenance 3.5 Transport Ventilator Setup & Primary Ventilation Modes
5 Chapter 3: Airway, Anesthesia, and Analgesics (Part 2)
3.6 Mechanical Ventilator Waveforms, Loops & Oxygenation Titration 3.7 Ventilator Alarm Troubleshooting & Peak vs Plateau Pressures 3.8 Rescue Airway Devices, Video Laryngoscopy & Surgical Cricothyrotomy 3.9 Neuromuscular Reversal & Vasoactive Airway Support 3.10 Transport Airway Management in Unique Environments & Extubation
6 Chapter 4: General Medical Patient
4.1 Sepsis, Severe Sepsis & Septic Shock Resuscitation 4.2 Endocrine Emergencies (DKA, HHS, Adrenal Crisis, Thyroid Storm) 4.3 Renal and Hepatic Emergencies in Transport
7 Chapter 5: Cardiac Patient
5.1 Acute Coronary Syndromes & Infarct Specific Complications 5.2 Invasive Hemodynamic Monitoring 5.3 Vasoactive & Inotropic Medication Titration 5.4 Mechanical Circulatory Support & Post-Cardiac Arrest Care
8 Chapter 6: Neurological Patient
6.1 Traumatic Brain Injury & Intracranial Pressure (ICP) Management 6.2 Acute Ischemic Stroke, Hemorrhagic Stroke & Subarachnoid Hemorrhage 6.3 Status Epilepticus, Spinal Cord Injury & Neurogenic Shock
9 Chapter 7: Respiratory Patient
7.1 Acute Respiratory Distress Syndrome (ARDS) & Lung-Protective Ventilation 7.2 Severe Asthma & COPD Exacerbations in Critical Care 7.3 Chest Tube Management, Pleural Drains & Tension Pneumothorax 7.4 Pulmonary Embolism, Pulmonary Hypertension & Transport Respiratory Meds
10 Chapter 8: Toxic Exposure and Environmental Patient
8.1 Toxicology Emergencies, Toxidromes & Antidote Therapy 8.2 Environmental Emergencies (Hypothermia, Hyperthermia, Frostbite) 8.3 Submersion, Diving Emergencies & Envenomation/HazMat
11 Chapter 9: Trauma and Burn Patient
9.1 Hemorrhagic Shock Resuscitation & Massive Transfusion Protocols (MTP) 9.2 Severe Thoracic & Abdominal Trauma Management 9.3 Thermal, Chemical & Electrical Burn Assessment & Fluid Resuscitation 9.4 Musculoskeletal Trauma, Pelvic Fractures & Compartment Syndrome
12 Chapter 10: Maternal and Fetal Medicine
10.1 High-Risk Obstetric Assessment & Hypertensive Disorders of Pregnancy 10.2 Obstetric Hemorrhage, Placental Abruption & Preterm Labor 10.3 Emergency Transport Delivery, Umbilical Cord Prolapse & Fetal Monitoring
13 Chapter 11: Pediatric Patient
11.1 Pediatric Critical Care Airway & Transport Ventilation 11.2 Pediatric Shock, Dehydration & Weight-Based Dosing 11.3 Neonatal Resuscitation Program (NRP) & Transport of the Critical Neonate
14 Chapter 12: Special Populations
12.1 Bariatric Critical Care Transport & Positional Management 12.2 Geriatric Critical Care & Patients with Specialized Medical Technology
15 Chapter 13: Professional Considerations
13.1 Legal Aspects, EMTALA & Transport Ethics 13.2 Quality Improvement, Transport Safety Research & Evidence-Based Practice
7.4 Pulmonary Embolism, Pulmonary Hypertension & Transport Respiratory Meds
Key Takeaways Explain This Topic AI
Pulmonary Embolism is categorized into Massive (hypotension SBP < 90 mmHg or vasopressor dependence), Submassive (RV strain/biomarker elevation without hypotension), and Low-Risk.
ECG and ECHO signs of acute right ventricular strain include S1Q3T3, new RBBB, T-wave inversions in V1-V4, elevated troponin/BNP, and McConnell's sign on echocardiogram.
Systemic thrombolysis with Alteplase (tPA 100 mg IV over 2 hours) is indicated in massive PE; unfractionated heparin (UFH) drip titrated to aPTT (60-80 s) is the anticoagulant of choice in transport.
Aggressive fluid boluses must be avoided in acute RV failure because RV overdistension shifts the interventricular septum into the left ventricle, compromising LV filling and worsening cardiogenic shock.
Continuous infusions or inhalations of pulmonary vasodilators (Epoprostenol, Treprostinil, Inhaled Nitric Oxide) must NEVER be stopped abruptly during transport due to short half-lives (3-6 min) and the risk of fatal rebound pulmonary hypertensive crisis.
Last updated: July 2026
Pulmonary Embolism, Pulmonary Hypertension & Transport Respiratory Meds
Pulmonary vascular emergencies present unique hemodynamic and ventilatory challenges during critical care transport. Understanding the pathophysiology of right ventricular (RV) failure, systemic thrombolysis, pulmonary vasodilator transport protocols, and specialized respiratory pharmacotherapy is critical for the critical care paramedic.
Pulmonary Embolism (PE): Risk Stratification
Pulmonary Embolism occurs when an embolus (most commonly thrombus originating from deep vein thrombosis of the lower extremities) occludes the pulmonary arterial circulation.
PE Classification Clinical Criteria Mortality Risk Primary Treatment Strategy
Massive PE Sustained hypotension ( SBP < 90 mmHg \text{SBP} < 90 \text{ mmHg} SBP < 90 mmHg for ≥ 15 min \ge 15 \text{ min} ≥ 15 min , or drop in SBP ≥ 40 mmHg \text{SBP} \ge 40 \text{ mmHg} SBP ≥ 40 mmHg ), or requirement for inotropic/vasopressor support, or cardiac arrest. > 30 − 50 % > 30 - 50\% > 30 − 50% Systemic Thrombolysis (or surgical/catheter embolectomy) + Anticoagulation.
Submassive PE Hemodynamically stable ( SBP ≥ 90 mmHg \text{SBP} \ge 90 \text{ mmHg} SBP ≥ 90 mmHg ) BUT with evidence of RV strain (ECHO/CT) OR myocardial necrosis (elevated Troponin / BNP). 5 − 15 % 5 - 15\% 5 − 15% Anticoagulation + close monitoring; rescue thrombolysis if destabilization occurs.
Low-Risk PE Hemodynamically stable with normal RV function and normal cardiac biomarkers. < 1 % < 1\% < 1% Systemic Anticoagulation.
Right Ventricular Strain Diagnostics
Acute pulmonary artery occlusion increases Right Ventricular afterload. The thin-walled RV dilates, fails, and impairs left ventricular filling through interventricular dependence . Acute Pulmonary Artery Occlusion
- │
- ▼
- Abrupt Rise in PVR
- │
- ▼
- Acute RV Dilation & Wall Stress
- │
- ┌───────┴───────┐
- ▼ ▼
- RV Myocardial Interventricular Septal Shift
- Ischemia (Bulges into Left Ventricle)
- (Troponin+) │
- ▼
- Reduced LV Preload & Stroke Volume
- │
- ▼
- Cardiogenic Shock
- 1. Electrocardiogram (ECG) Manifestations
Sinus Tachycardia : Most common arrhythmia present.
S1Q3T3 Pattern : Deep S wave in Lead I, prominent Q wave in Lead III, inverted T wave in Lead III (specific for acute RV strain, found in ∼ 20 % \sim 20\% ∼ 20% of cases).
Right Bundle Branch Block (RBBB) : New complete or incomplete RBBB.
Right Axis Deviation : Mean QRS axis > + 90 ∘ > +90^\circ > + 9 0 ∘ .
T-Wave Inversions : Inverted T waves in precordial leads V1–V4 and inferior leads II, III, aVF.
2. Echocardiography & Biomarkers
McConnell's Sign : Distinctive echocardiographic pattern showing hypokinesis of the RV free wall with normal wall motion at the RV apex.
RV/LV Diameter Ratio : RV/LV ratio > 0.9 \text{RV/LV ratio} > 0.9 RV/LV ratio > 0.9 or > 1.0 > 1.0 > 1.0 indicates acute RV enlargement.
D-Shaped Left Ventricle : Paradoxical bowing of the interventricular septum into the LV cavity during systole and diastole.
Cardiac Troponin I/T : Indicates RV microvascular myocardial ischemia.
B-type Natriuretic Peptide (BNP / NT-proBNP) : Elevated secondary to acute RV wall stretch.
- Critical Care Management of Massive PE
- 1. Systemic Thrombolytic Therapy
Thrombolysis rapidly dissolves clot mass, reduces pulmonary vascular resistance, and restores RV function in Massive PE.
Standard Alteplase (tPA) Protocol : 100 mg 100 \text{ mg} 100 mg IV infusion over 2 hours.
Cardiac Arrest / Extreme Instability Protocol : 50 mg 50 \text{ mg} 50 mg IV push over 2 minutes (may repeat once in 15 minutes).
Absolute Contraindications to Thrombolysis :
Prior hemorrhagic stroke or stroke of unknown origin at any time.
Ischemic stroke within the preceding 6 months.
Central nervous system neoplasm or structural vascular lesion.
Recent major trauma, surgery, or head injury within preceding 3 weeks.
Active internal bleeding (excluding menses).
2. Anticoagulation Protocol
Unfractionated Heparin (UFH) is the preferred agent during transport due to its rapid onset, short half-life ( 60 − 90 minutes 60-90 \text{ minutes} 60 − 90 minutes ), and full reversibility with Protamine Sulfate ( 1 mg 1 \text{ mg} 1 mg protamine per 100 units 100 \text{ units} 100 units heparin).
Dosing : IV bolus 80 units/kg 80 \text{ units/kg} 80 units/kg followed by continuous infusion at 18 units/kg/hr 18 \text{ units/kg/hr} 18 units/kg/hr , titrated to target aPTT of 60–80 seconds ( 1.5 − 2.5 × 1.5 - 2.5 \times 1.5 − 2.5 × control).
Resuscitation Hazards in Acute RV Failure
Managing acute right heart failure in PE requires strict fluid restriction and specific vasopressor choices:
The Fluid Bolus Trap!
AVOID AGGRESSIVE FLUID BOLUSES : The thin-walled right ventricle is extremely volume-sensitive. Fluid boluses over-stretch the RV, worsen RV ischemia, shift the septum further into the LV, and decrease cardiac output!
Fluid Rule : If hypovolemic, give no more than a single cautious challenge of 250 − 500 mL 250-500 \text{ mL} 250 − 500 mL isotonic fluid.
Inotrope & Vasopressor Selection
Agent Mechanism Clinical Role in RV Failure
Norepinephrine Alpha-1 & Beta-1 agonist First-line agent . Restores systemic arterial pressure, maintaining Right Coronary Artery perfusion pressure without increasing PVR.
Vasopressin V1a receptor agonist Potent systemic vasoconstrictor; at low doses ( 0.03 units/min 0.03 \text{ units/min} 0.03 units/min ), it causes minimal pulmonary vascular constriction.
Dobutamine Beta-1 & Beta-2 agonist Inotrope; enhances RV contractility. Caution: can cause systemic vasodilation/hypotension; combine with Norepinephrine.
Pulmonary Arterial Hypertension (PAH) Transport Rules
Pulmonary Arterial Hypertension (PAH) is defined by a mean Pulmonary Artery Pressure ( mPAP \text{mPAP} mPAP ) > 20 mmHg > 20 \text{ mmHg} > 20 mmHg at rest with pulmonary vascular resistance ( PVR \text{PVR} PVR ) > 2 Wood units > 2 \text{ Wood units} > 2 Wood units .
Continuous Targeted Pulmonary Vasodilator Therapies
Patients with severe PAH are maintained on continuous targeted pulmonary vasodilator infusions or inhalations:
Prostacyclins : Inhaled Epoprostenol ( Flolan / Veletri ), Treprostinil ( Remodulin / Tyvaso ), Continuous IV Epoprostenol.
Inhaled Nitric Oxide (iNO) : Selective pulmonary vasodilator gas administered via specialized transport delivery systems ( 20 − 40 ppm 20-40 \text{ ppm} 20 − 40 ppm ).
THE CRITICAL MANDATE: NEVER INTERRUPT PROSTACYCLIN INFUSIONS
Half-Life Alert : Intravenous Epoprostenol has an extremely short half-life of 3 to 6 minutes !
Rebound Hypertensive Crisis : Abrupt interruption of epoprostenol or treprostinil (due to depleted pump battery, line kink, or empty syringe) triggers catastrophic, fatal rebound pulmonary vasoconstriction, acute RV collapse, and immediate cardiac arrest.
Transport Precautions :
Transport with a dedicated backup infusion pump loaded and running in parallel.
Prepare a backup syringe of epoprostenol/treprostinil prior to departure.
Maintain dedicated IV lines (NEVER flush or co-infuse other medications through a prostacyclin line!).
- Transport Respiratory Pharmacotherapy
- Inhaled Mucolytics & Hypertonic Saline
Hypertonic Saline ( 3 % 3\% 3% or 7 % 7\% 7% ) : Nebulized to induce osmotic draw of water into airways, rehydrating thick mucus in cystic fibrosis or bronchiectasis.
Acetylcysteine (Mucomyst) : 3 − 5 mL 3-5 \text{ mL} 3 − 5 mL of 10 % 10\% 10% or 20 % 20\% 20% solution nebulized to break disulfide bonds in mucoproteins. Caution : Can trigger acute bronchospasm; always co-administer with an inhaled beta-agonist (e.g., albuterol).
Racemic Epinephrine
Dose : 0.5 mL 0.5 \text{ mL} 0.5 mL of 2.25 % 2.25\% 2.25% solution diluted in 3 mL 3 \text{ mL} 3 mL normal saline via nebulizer.
Mechanism : Alpha-1 agonist stimulation induces mucosal vasoconstriction, dramatically reducing upper airway edema in post-extubation stridor and croup.